Evidence map›Paper›PMID 35291829›Full record

ArticleThe Journal of international medical research2022

Metabolic complete tumor response in a patient with

Ivana Puliafito, Francesca Esposito, Gabriele Raciti, Paolo Giuffrida, Claudia Caltavuturo, Cristina Colarossi, Stefania Munao, Dorotea Sciacca, Dario Giuffrida

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of international medical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Dose Reduction ofCancer diagnosis & prognosis
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Ivana PuliafitoMedical Oncology, Istituto Oncologico del Mediterraneo, Viagrande, Catania, Italy.
Francesca EspositoIOM Ricerca, Viagrande, Catania, Italy.ORCID https://orcid.org/0000-0002-1597-9034
Gabriele RacitiIOM Ricerca, Viagrande, Catania, Italy.
Paolo GiuffridaMedical Oncology, Istituto Oncologico del Mediterraneo, Viagrande, Catania, Italy.ORCID https://orcid.org/0000-0002-4628-1130
Claudia CaltavuturoRadiology, Istituto Oncologico del Mediterraneo, Viagrande, Catania, Italy.ORCID https://orcid.org/0000-0001-7506-3223
Cristina ColarossiPathology, Istituto Oncologico del Mediterraneo, Viagrande, Catania, Italy.
Stefania MunaoMedical Oncology, Istituto Oncologico del Mediterraneo, Viagrande, Catania, Italy.
Dorotea SciaccaMedical Oncology, Istituto Oncologico del Mediterraneo, Viagrande, Catania, Italy.
Dario GiuffridaMedical Oncology, Istituto Oncologico del Mediterraneo, Viagrande, Catania, Italy.ORCID https://orcid.org/0000-0001-6404-2304
Istituto Oncologico Veneto · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) are the first-line treatment for

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAfatinibErbB ReceptorsFemaleGenes, erbB-1HumansMiddle AgedMutationAfatinibErbB Receptorsadverse eventAfatinibcase reportepidermal growth factor receptor mutationnon-small cell lung cancertyrosine kinase inhibitor

Identifiers

PMID35291829
PMCPMC8943310
OpenAlexW4220955097

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.